Wichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt
April 27, 2021 01:00 ET
|
Novartis Pharma AG
Der Nettoumsatz sank im ersten Quartal um –2% (kWk¹, +1% USD) infolge der COVID-19-bedingten Vorratskäufe im Vorjahr (rund USD 0,4 Milliarden) Die Geschäftseinheit Pharmaceuticals blieb auf...
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
March 30, 2021 01:15 ET
|
Novartis Pharma AG
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74Broad...
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
March 23, 2021 02:15 ET
|
Novartis Pharma AG
Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive...
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
March 15, 2021 06:00 ET
|
Novartis Pharma AG
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious,...
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
March 09, 2021 01:00 ET
|
Novartis Pharma AG
Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed...
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelle
March 02, 2021 09:26 ET
|
Novartis International AG
Les actionnaires approuvent la 24e augmentation consécutive du dividende qui passe à CHF 3.– (+1,7%) par action pour l’année 2020, soit un rendement de 3,8%1 et une distribution du free cash-flow...
Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gut
March 02, 2021 09:26 ET
|
Novartis International AG
Die Aktionäre bewilligen die 24. Dividendenerhöhung in Folge. Für 2020 wird die Dividende auf CHF 3.00 (+1,7%) je Aktie erhöht, was einer Rendite von 3,8%1 und einem Anteil des freien...
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
March 02, 2021 09:26 ET
|
Novartis International AG
Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg...
Novartis Entresto® granted expanded indication in chronic heart failure by FDA
February 16, 2021 13:23 ET
|
Novartis International AG
Entresto is the first and only therapy approved in the US to treat patients diagnosed with guideline-defined heart failure to include both those with heart failure with reduced ejection fraction...
Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis
January 29, 2021 12:05 ET
|
Novartis International AG
Kesimpta is a targeted B-cell therapy that delivers superior efficacy with a similar safety and tolerability profile compared with teriflunomide, a first-line treatment in MS1CHMP opinion is based on...